Daniel Aletaha
#117,353
Most Influential Person Now
Researcher
Daniel Aletaha's AcademicInfluence.com Rankings
Daniel Aletahamedical Degrees
Medical
#1705
World Rank
#2072
Historical Rank
Rheumatology
#10
World Rank
#11
Historical Rank
Daniel Aletahabiology Degrees
Biology
#6890
World Rank
#9701
Historical Rank
Immunology
#361
World Rank
#375
Historical Rank
Download Badge
Medical Biology
Daniel Aletaha's Degrees
- PhD Biomedical Sciences University of Vienna
- Masters Biotechnology University of Vienna
- Bachelors Biotechnology University of Vienna
Why Is Daniel Aletaha Influential?
(Suggest an Edit or Addition)Daniel Aletaha's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative (2010) (6830)
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. (2010) (5183)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010) (4048)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) (2474)
- Treating rheumatoid arthritis to target: recommendations of an international task force (2010) (1927)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013) (1711)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update (2020) (1453)
- Rheumatoid arthritis (2016) (1225)
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials (2011) (1163)
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force (2015) (1155)
- New therapies for treatment of rheumatoid arthritis (2007) (966)
- Diagnosis and Management of Rheumatoid Arthritis: A Review (2018) (931)
- Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score (2005) (922)
- Rheumatoid arthritis (2018) (893)
- European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update (2015) (854)
- The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. (2005) (772)
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate (2008) (656)
- European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies (2011) (477)
- Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (2017) (476)
- Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. (2005) (475)
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update (2020) (433)
- 2016 update of the EULAR recommendations for the management of early arthritis (2016) (375)
- Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges (2015) (362)
- Distinctions Between Diagnostic and Classification Criteria? (2015) (357)
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. (2011) (354)
- The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. (2010) (322)
- Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. (2008) (318)
- Depletion of Endothelial Progenitor Cells in the Peripheral Blood of Patients With Rheumatoid Arthritis (2005) (307)
- Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. (2006) (300)
- Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score (2015) (293)
- Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. (2006) (281)
- Evidence for treating rheumatoid arthritis to target: results of a systematic literature search (2010) (280)
- Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update (2015) (276)
- Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis (2010) (268)
- Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. (2003) (259)
- Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade (2008) (256)
- Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative (2013) (244)
- Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. (2007) (244)
- A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. (2009) (231)
- European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects (2011) (226)
- Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. (2012) (225)
- Proposal for a new nomenclature of disease-modifying antirheumatic drugs (2013) (218)
- 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations (2014) (210)
- The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. (2002) (207)
- Minimal disease activity for rheumatoid arthritis: a preliminary definition. (2005) (203)
- Assessing remission in clinical practice. (2007) (202)
- Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). (2008) (191)
- EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis (2016) (190)
- The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I (2010) (187)
- Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction (2011) (173)
- SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity (2021) (164)
- Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis (2010) (164)
- Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis (2010) (158)
- The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. (2007) (146)
- A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. (2007) (144)
- Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. (2011) (139)
- The definition and measurement of disease modification in inflammatory rheumatic diseases. (2006) (137)
- The pathogenesis of rheumatoid arthritis: new insights from old clinical data? (2012) (137)
- Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review (2013) (135)
- Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. (2009) (135)
- Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. (2011) (132)
- Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction (2011) (128)
- Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity (2020) (126)
- Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. (2002) (126)
- EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria (2013) (121)
- Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions (2012) (121)
- Impact of comorbidity on physical function in patients with rheumatoid arthritis (2009) (119)
- Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs (2014) (116)
- EULAR definition of difficult-to-treat rheumatoid arthritis (2020) (114)
- Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. (2011) (112)
- SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response (2021) (111)
- Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis (2012) (110)
- Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials (2009) (106)
- Therapeutic strategies in early rheumatoid arthritis. (2005) (103)
- Anti-TNF in rheumatoid arthritis: an overview (2015) (99)
- Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy (2007) (94)
- Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. (2007) (93)
- Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire (2011) (93)
- Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? (2005) (93)
- Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis (2009) (88)
- Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study (2003) (86)
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement (2020) (85)
- The assessment of disease activity in rheumatoid arthritis. (2010) (85)
- Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative (2010) (84)
- Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study (2017) (84)
- Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results (2007) (83)
- The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? (2008) (82)
- Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative (2012) (81)
- Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10 (2011) (81)
- Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis (2003) (79)
- Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis (2007) (79)
- Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials (2015) (76)
- Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index (2012) (75)
- Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008 (2009) (73)
- Forget personalised medicine and focus on abating disease activity (2012) (73)
- Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity (2012) (73)
- Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. (2009) (73)
- Disease activity measures for rheumatoid arthritis. (2007) (72)
- What should be our treatment goal in rheumatoid arthritis today? (2006) (69)
- Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years (2002) (69)
- Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. (2009) (69)
- Colchicine for acute gout. (2014) (68)
- Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials (2005) (68)
- Rheumatoid arthritis and falls: the influence of disease activity. (2012) (68)
- Developments in the clinical understanding of rheumatoid arthritis (2009) (67)
- Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing (2008) (66)
- Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years (2011) (65)
- Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations (2008) (65)
- Assessing Quality of Sleep in Patients with Rheumatoid Arthritis (2009) (64)
- Reporting of long-term extension studies: lack of consistency calls for consensus (2011) (64)
- Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point (2015) (63)
- The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. (2006) (62)
- Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey (2004) (62)
- Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. (2013) (61)
- Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression (2011) (61)
- Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis: Superior Correlation With Magnetic Resonance Imaging–Detected Synovitis and Radiographic Progression (2014) (60)
- Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression (2016) (60)
- Scores for all seasons: SDAI and CDAI. (2014) (59)
- Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition (2017) (58)
- Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey (2018) (58)
- Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. (2015) (58)
- Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. (2015) (57)
- Pro-inflammatory cytokines in rheumatoid arthritis (2005) (56)
- Mapping hand functioning in hand osteoarthritis: comparing self-report instruments with a comprehensive hand function test. (2007) (54)
- Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). (2011) (54)
- Remission of rheumatoid arthritis: should we care about definitions? (2006) (53)
- Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. (2012) (53)
- The need for new classification criteria for rheumatoid arthritis. (2005) (53)
- Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria (2009) (51)
- The importance of reporting disease activity states in rheumatoid arthritis clinical trials. (2008) (50)
- Power Doppler sonography and pulse-inversion harmonic imaging in evaluation of rheumatoid arthritis synovitis. (2007) (50)
- The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. (2009) (49)
- Risk profiling for a refractory course of rheumatoid arthritis. (2019) (49)
- Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. (2015) (48)
- Fever of unknown origin (FUO) revised (2016) (48)
- Remission by composite scores in rheumatoid arthritis: are ankles and feet important? (2007) (48)
- Activity assessments in rheumatoid arthritis (2008) (45)
- Does damage cause inflammation? Revisiting the link between joint damage and inflammation (2009) (43)
- Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort (2012) (43)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update (2022) (42)
- Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design (2009) (41)
- Therapeutic implications of autoantibodies in rheumatoid arthritis (2016) (41)
- Early rheumatoid arthritis (2006) (40)
- Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal? (2020) (40)
- Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis (2012) (39)
- Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents (2009) (39)
- Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria (2017) (38)
- The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. (2014) (38)
- Relationship between radiographic joint space narrowing, sonographic cartilage thickness and anatomy in rheumatoid arthritis and control joints (2014) (38)
- Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology (2014) (38)
- Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure (2006) (37)
- [Classification of rheumatoid arthritis]. (1982) (36)
- EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis (2021) (36)
- Challenges of predicting treatment response in patients with rheumatoid arthritis (2005) (35)
- An overview of psoriatic arthritis – epidemiology, clinical features, pathophysiology and novel treatment targets (2016) (35)
- Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets (2019) (34)
- Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature. (2014) (33)
- Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial (2021) (32)
- The burden of rheumatoid arthritis and access to treatment: a medical overview (2007) (32)
- Precision medicine and management of rheumatoid arthritis. (2020) (31)
- Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. (2018) (31)
- Diagnostic and Prognostic Value of Antibodies and Soluble Biomarkers in Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review (2011) (30)
- The effects of structural damage on functional disability in psoriatic arthritis (2017) (30)
- Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. (2016) (29)
- Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study (2019) (29)
- Treating rheumatic patients with a malignancy (2011) (28)
- Patients with rheumatoid arthritis in clinical care (2004) (27)
- Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data (2008) (27)
- Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients (2015) (26)
- Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis (2019) (26)
- Monitoring rheumatoid arthritis (2011) (25)
- Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? (2018) (24)
- 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice (2020) (24)
- Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points (2016) (24)
- Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients (2012) (24)
- Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. (2019) (23)
- Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis (2008) (23)
- Value of self-performed joint counts in rheumatoid arthritis patients near remission (2012) (23)
- Persistence of subclinical sonographic joint activity in rheumatoid arthritis in sustained clinical remission (2015) (23)
- The public neglect of rheumatic diseases: insights from analyses of attendees in a musculoskeletal disease awareness activity (2007) (22)
- Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis. (2002) (22)
- EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis (2021) (21)
- Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis (2020) (21)
- Complexities in defining remission in rheumatic diseases. (2006) (21)
- Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. (2019) (20)
- DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease. (2003) (20)
- Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities (2017) (20)
- Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis (2021) (20)
- Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial (2018) (20)
- Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind? (2005) (19)
- Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis (2021) (19)
- Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. (2020) (19)
- Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates (2015) (18)
- Compression Test (Gaenslen's Squeeze Test) Positivity, Joint Tenderness, and Disease Activity in Patients With Rheumatoid Arthritis (2013) (18)
- Combination Therapy for Pain Management in Inflammatory Arthritis: A Cochrane Systematic Review (2012) (17)
- Achieving Clinical Remission for Patients With Rheumatoid Arthritis. (2019) (17)
- EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology (2018) (17)
- Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. (2020) (17)
- Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial (2022) (17)
- The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. (2006) (16)
- Disease activity assessment in patients with psoriatic arthritis. (2018) (16)
- The use of data from early arthritis clinics for clinical research. (2009) (16)
- Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. (2013) (15)
- Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab (2020) (15)
- Treatment of gout patients with impairment of renal function: a systematic literature review. (2014) (15)
- From the item to the outcome: the promising prospects of PROMIS (2010) (14)
- The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS (2022) (14)
- The use of databases for quality assessment in rheumatoid arthritis. (2007) (13)
- Rheumatism collaborative initiative Rheumatology / European League Against an American College of 2010 Rheumatoid arthritis classification criteria : (2010) (13)
- How Do Gastrointestinal or Liver Comorbidities Influence the Choice of Pain Treatment in Inflammatory Arthritis? A Cochrane Systematic Review (2012) (13)
- Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider (2018) (13)
- Increasing both specificity and sensitivity of SARS-CoV-2 antibody tests by using an adaptive orthogonal testing approach (2020) (13)
- Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study. (2016) (13)
- Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis (2021) (13)
- recommendations of an international task force Treating rheumatoid arthritis to target (2010) (13)
- Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity (2017) (12)
- Combination therapy for pain management in inflammatory arthritis (2010) (12)
- Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. (2017) (12)
- Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study (2007) (12)
- Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative (2011) (11)
- Who are the young professionals working in the field of rheumatology in Europe and what are their needs? An EMEUNET (EMerging EUlar NETwork) survey (2012) (11)
- Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi‐solid colony growth (2001) (11)
- The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS (2022) (11)
- FRI0498 Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab (2017) (10)
- Pre-arthritis: a concept whose time has come (2006) (10)
- Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example (2014) (10)
- Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns (2019) (10)
- Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study (2022) (10)
- Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years (2019) (10)
- The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin‐1 Mediated Autoinflammatory Diseases: Cryopyrin‐Associated Periodic Syndromes, Tumour Necrosis Factor Receptor‐Associated Periodic Syndrome, Mevalonate Kinase Deficiency, an (2022) (10)
- Interleukin 6: The biology behind the therapy (2018) (10)
- The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. (2019) (10)
- Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. (2020) (10)
- The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases (2016) (9)
- An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. (2019) (9)
- The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, an (2022) (9)
- Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis (2016) (9)
- Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: New aspects after the fall of the pyramid and the rise of new therapeutics (2003) (9)
- Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study (2018) (9)
- New insights into the measurement of disease activity in rheumatoid arthritis (2015) (9)
- Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data (2009) (8)
- Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study (2022) (8)
- A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis (2021) (7)
- Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study (2020) (7)
- Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients (2018) (7)
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis (2022) (7)
- Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight–joint Disease Activity Score, C-reactive protein level and patient global assessment (2021) (7)
- Advances in anti-inflammatory therapy. (2002) (7)
- [Measuring disease activity for rheumatoid arthritis]. (2006) (7)
- Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies (2021) (7)
- Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment (2021) (7)
- Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE) (2021) (7)
- Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3 (2021) (7)
- Response to: Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al (2021) (7)
- Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients (2017) (6)
- Are we failing patients in our assessment of treatment failure? (2019) (6)
- Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free? (2021) (6)
- Nothing lasts forever - a critical look at sustained remission (2012) (6)
- Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis (2022) (6)
- Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. (2021) (6)
- Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial (2022) (6)
- Glucocorticoid treatment in rheumatoid arthritis: low-dose therapy does not reduce responsiveness to higher doses. (2008) (5)
- Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials (2016) (5)
- Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al (2021) (5)
- To DAPSA or not to DAPSA? That is not the question (2018) (5)
- Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. (2010) (5)
- Considering comorbidity in managing rheumatic diseases: going where trials cannot go (2011) (5)
- Pseudoerosions of Hands and Feet in Rheumatoid Arthritis: Anatomic Concepts and Redefinition (2019) (5)
- [Rheumatoid arthritis. Target outcome for treatment]. (2009) (4)
- A critical review of the reproductive safety of Leflunomide (2019) (4)
- Pain management for inflammatory arthritis and gastrointestinal or liver comorbidity (2011) (4)
- Baseline predictors of different types of treatment success in rheumatoid arthritis (2021) (4)
- Tofacitinib for Psoriatic Arthritis. (2018) (4)
- American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision (2022) (4)
- Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results (2022) (4)
- In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora (2021) (4)
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis (2022) (4)
- Information technology concerning SDAI and CDAI. (2016) (4)
- SAT0145 EFFICACY AND SAFETY OF UPADACITINIB MONOTHERAPY IN MTX-NAÏVE PATIENTS WITH EARLY ACTIVE RA RECEIVING TREATMENT WITHIN 3 MONTHS OF DIAGNOSIS: A POST-HOC ANALYSIS OF THE SELECT-EARLY (2020) (4)
- Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis (2020) (4)
- POS0092 HERPES ZOSTER IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM (2021) (4)
- The many faces of psoriatic arthritis – a challenge to treatment to target? (2016) (4)
- Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology (2020) (4)
- SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future (2021) (3)
- Considering new lessons about the use of IL-6 inhibitors in arthritis (2018) (3)
- Therapy: Challenging the course of RA: time for drug-free remission? (2010) (3)
- Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls (2022) (3)
- EULAR recommendations for the inclusion of patient representatives in scientific projects: A EULAR initiative (2011) (3)
- American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision (2022) (3)
- Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis (2021) (3)
- UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, (2010) (3)
- Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables (2021) (3)
- FRI0043 JOINT SPACE NARROWING PRECEDES EROSIVE RADIOGRAPHIC DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS (2020) (3)
- Medikament??se Therapie (2012) (3)
- Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis (2008) (3)
- Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency (2022) (3)
- Targeting IL-6: A review of data (2018) (3)
- THU0127 Development of Draft Criteria for Arthralgia that is Clinically Suspect for Progression to Rheumatoid Arthritis; Results of Phase 1 (2015) (3)
- AB0292 Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis – analysis using the save study cohort (2013) (3)
- Dorso-ventral osteophytes of interphalangeal joints correlate with cartilage damage and synovial inflammation in hand osteoarthritis: a histological/radiographical study (2022) (3)
- The health assessment questionnaire in routine clinical practice (2007) (2)
- FRI0051 The risk of aseptic arthroplasty loosening in patients with rheumatoid arthritis (2018) (2)
- Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis (2020) (2)
- [Clinical outcome measures in hand- and finger joint osteoarthritis from the patient perspective]. (2006) (2)
- Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis (2022) (2)
- SAT0081 The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies (AAPA) in Rheumatoid Arthritis Patients Starting Their First Dmard Treatment on Methotrexate (2016) (2)
- Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials (2019) (2)
- Reexamining Remission Definitions in Rheumatoid Arthritis: Considering Disease Activity Score in 28 Joints, C‐Reactive Protein, and Patient Global Assessment (2021) (2)
- Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022 (2023) (2)
- IgA rheumatoid factor in rheumatoid arthritis (2022) (2)
- Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers (2022) (2)
- OP0059 AUTOSCORA: DEEP LEARNING TO AUTOMATE SCORING OF RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS (2020) (2)
- ACR Convergence 2022 Abstract Supplement. (2022) (2)
- TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation. (2022) (2)
- P698 The risk of developing subsequent immune mediated inflammatory diseases: a retrospective matched cohort study. (2017) (2)
- OP0126 INFECTIONS AND SERIOUS INFECTIONS IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM (2021) (2)
- Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. (2020) (2)
- Management of rheumatoid arthritis: what happens and what does not happen in real life (2016) (2)
- Abstracts from The College of Podiatry Annual Conference 2016 (2017) (2)
- FRI0092 Influence of Temperature and Humidity on Disease Activity in Rheumatoid Arthritis (2016) (2)
- AB0217 The prognostic value of iga autoantibodies (rheumatoid factor and acpa) for prediction of therapeutic responses to anti-tnf therapy in patients with rheumatoid arthritis (2017) (2)
- Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis (2021) (2)
- OP0127 CONFOUNDING EFFECTS OF CONTINUED METHOTREXATE IN PLACEBO ARMS (PLC) OF RHEUMATOID ARTHRITIS (RA) CLINICAL TRIALS – A POST-HOC ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS (RCTS) (2021) (2)
- Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier (2018) (2)
- POS0676 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY (2022) (2)
- THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS (2020) (2)
- CHAPTER 9A – Outcome Measurement in Rheumatoid Arthritis: Disease Activity (2009) (2)
- FRI0133 Understanding Anemia in Rheumatoid Arthritis: The Association of Hemoglobin and Hepcidin Levels with Clinical Disease Activity and Acute Phase Response (2016) (2)
- Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs) (2022) (2)
- Seminar: Rheumatoid Arthritis (2016) (2)
- FRI0182 Development of A Multimorbidity Index: Impact on Quality of Life Using A Rheumatoid Arthritis Cohort (2014) (2)
- A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases (2022) (2)
- COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report (2022) (2)
- AB0272 Rheumatoid factor determines structural progression of rheumatoid arthritis also independently of disease activity (2013) (1)
- Web figure 1 (2013) (1)
- Monitoring disease activity in rheumatoid arthritis: an imperative (2008) (1)
- SAT0474 Differences of clinical and ultrasound (US) remission in rheumatoid arthritis (RA) depend on the stringency of the us methodology (2013) (1)
- Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient? (2019) (1)
- FRI0585 Prevalence of anti-acetylated protein antibodies in inflammatory arthritis, osteoarthritis, connective tissue diseases and its discriminative capacity as diagnostic marker for early rheumatoid arthritis (2018) (1)
- Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty‐Eight–Joint Disease Activity Score, C‐Reactive Protein Level, and Patient Global Assessment (2021) (1)
- FRI0094 Kidney Function and Effectiveness of Methotrexate Treatment in Rheumatoid Arthritis Patients (2015) (1)
- Genetic risk scores in inflammatory arthritis: a new era? (2020) (1)
- AB0303 When it's the First, Stay on the First and Fight Anemia! Analyses of Treatment Retention in an Observational Rheumatoid Arthritis Cohort (2015) (1)
- Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis (2022) (1)
- SAT0104 INITIAL EVIDENCE FOR THE NEED OF A DUAL TREAT-TO-TARGET STRATEGY IN PATIENTS WITH RHEUMATOID ARTHRITIS (2019) (1)
- OP0076 Risk of developing additional immune mediated manifestations for patients with systemic arthritides (2017) (1)
- Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al (2020) (1)
- Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update (2022) (1)
- Response to: ‘Correspondence on ‘Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis’’ by Dumoulin et al (2021) (1)
- THU0246 Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified disease activity index for psoriatic arthritis (DAPSA) based on 28 joints? (2018) (1)
- Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis (2022) (1)
- [Activity-score based therapy in rheumatoid arthritis]. (2006) (1)
- OP0247 An improved matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases (2017) (1)
- Torque Teno Virus Quantification for Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis. (2021) (1)
- Reflections on a contemporary European tragedy (2022) (1)
- Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases (2022) (1)
- FRI0090 Fulfilling only three of four ACR/EULAR boolean remission criteria is not predictive of subsequent full remission (2013) (1)
- FRI0602 Eular ‘points to consider’ for the conduction of workforce requirement studies in rheumatology (2018) (1)
- 96 – Evaluation and outcomes of patients with rheumatoid arthritis (2015) (1)
- Einternational panel of rheumatologists in the research and expert opinion of a broad arthritis : integrating systematic literature undifferentiated peripheral inflammatory on how to investigate and follow-up Multinational evidence-based recommendations (2010) (0)
- POS0653 IMPACT OF UPADACITINIB OR ADALIMUMAB AS INITIAL THERAPY ON THE ACHIEVEMENT OF 48-WEEK TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: POST HOC ANALYSIS OF A PHASE 3 STUDY (2021) (0)
- Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study (2022) (0)
- Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology (2022) (0)
- SAT0608-HPR EULAR POINTS TO CONSIDER FOR THE DETECTION, ASSESSMENT AND MANAGEMENT OF NON-ADHERENCE IN PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES (2020) (0)
- AB0417 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS (2019) (0)
- FRI0516 Disease activity is primarily associated with rheumatoid factor (RF) and not antibodies to citrullinated peptides (ACPA) (2013) (0)
- POS0701 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO csDMARDs: RESULTS FROM RA-BEYOND UP TO 7 YEARS OF TREATMENT (2022) (0)
- OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions (2023) (0)
- POS0664 RADIOGRAPHIC CHANGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ESTIMATED BASELINE YEARLY PROGRESSION ≥5 OR <5: POST HOC ANALYSIS OF TWO PHASE 3 TRIALS OF FILGOTINIB (2022) (0)
- 08.28 The prognostic value of iga autoantibodies (rheumatoid factor and acpa) for prediction of the therapeutic response to anti-tnf therapy in patients with rheumatoid arthritis (2017) (0)
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica (2023) (0)
- THU0186 Magnitude and duration of early response with tofacitinib: post-hoc analysis of two phase 3, placebo-controlled studies (2017) (0)
- Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis (2023) (0)
- AB0185 Clinical joint involvement is decisive for radiographic progression (2013) (0)
- Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al (2020) (0)
- Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach (2023) (0)
- SAT0100 The determinants of refractory rheumatoid arthritis (2018) (0)
- AB1245-HPR New health technologies and lifestyle management for patients with osteoarthritis (2017) (0)
- POS0682 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO bDMARDs: RESULTS FROM RA-BEYOND FOLLOWING 6.9 YEARS OF TREATMENT (2022) (0)
- AB0298 Relation between Disease Activity Indices and their Individual Components and Radiographic Progression in Rheumatoid Arthritis: A Systematic Literature Review (2014) (0)
- POS1096 CHARACTERIZATION OF A PsA COHORT IN CLINICAL ROUTINE CARE USING THE DAPSA AND ITS CORE-SET PARAMETERS. (2022) (0)
- OP0229PHASE II CLINICAL TRIALS SYSTEMATICALLY OVERESTIMATE TREATMENT EFFECTS OF SUBSEQUENT PHASE III TRIALS IN RHEUMATOID ARTHRITIS (2019) (0)
- How FABulous is PEGgy? Certoliziumab Pegol from the Bench to the Patients (2014) (0)
- SAT0084 Osteophytes Increase the Ambiguity of Clinical Evaluation of Joint Swelling in Rheumatoid Arthritis (2015) (0)
- Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to Adalimumab. (2023) (0)
- THU0133 TENDERNESS CAN BE REGARDED AS A SIGN OF INFLAMMATION IN RHEUMATOID ARTHRITIS (2019) (0)
- AB0766 ACCURACY OF PATIENT REPORTED OUTCOME REPORTING IN RANDOMIZED CONTROLLED TRIALS IN PSORIATIC ARTHRITIS (2020) (0)
- CME Multiple Choice Questions (1998) (0)
- OP-BRHE120108 2051..2057 (2012) (0)
- THU0101 TORQUE TENO VIRAL LOAD FOR MONITORING OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS (2019) (0)
- Treating Rheumatoid Arthritis to Target: Background and Prospects (2011) (0)
- Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study (2023) (0)
- POS0485 TRAJECTORY CLUSTERS OF RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS: ASSOCIATIONS WITH CLINICAL VARIABLES (2021) (0)
- The diagnostic and prognostic value of IgG and IgA anti-citrullinated protein antibodies in patients with early rheumatoid arthritis (2023) (0)
- THU0633 Temperature sensitivity in patients with rheumatoid arthritis (2017) (0)
- THU0112 DIAGNOSTIC PERFORMANCE OF ANTI-CYCLIC CITRULLINATED PEPTIDE (CCP) 2 AND CCP3.1 ASSAYS IN EARLY RHEUMATOID ARTHRITIS (2020) (0)
- SAT0160 PREFERENCES OF EUROPEAN RHEUMATOLOGISTS ON THE DISCONTINUATION OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS (2019) (0)
- Reply (2014) (0)
- FRI0108 Clinical and Economic Outcomes of Dose Tapering and Withdrawal (DT&W) of Biologics Compared to their Maintainence Upon Achieving Stable Disease Activity in Rheumatoid Arthritis (RA) Patients (2015) (0)
- P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment (2023) (0)
- SAT0515 Sonographic and clinical examination of tendon involvement in hand osteoarthritis (2017) (0)
- AB0205 TENDERNESS AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS (2022) (0)
- AB0377 Clinical, Functional, and Structural Consequences of Targeting Low Disease Activity Rather than Remission in Early and Established Rheumatoid Arthritis Using Methotrexate or Methotrexate plus Adalimumab (2014) (0)
- FRI0582 Fluctuating Levels of Rheumatoid Factor Predict Progression of Rheumatoid Arthritis, but Not Independent of Disease Activity (2016) (0)
- POS0638 RECOMMENDATIONS FOR COST-EFFECTIVE USE OF BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN INFLAMMATORY ARTHRITIS: RESULTS FROM AN INTERNATIONAL DELPHI STUDY (2022) (0)
- POS0145 PREDICTORS OF PSORIATIC ARTHRITIS DEVELOPMENT IN PSORIASIS PATIENTS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS (2021) (0)
- From individualised treatment goals to personalised rehabilitation in osteoarthritis: a longitudinal prospective mapping study using the WHO international classification for functioning, disability and health (2022) (0)
- THU0103 Differences in Patients with Rheumatoid Arthritis who Achieved DAS Remission or SDAI Remission but not Boolean Remission (2015) (0)
- Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al (2023) (0)
- THU0162 LIKELIHOOD OF CLINICAL WORSENING AMONG RHEUMATOID ARTHRITIS PATIENTS WHO ACHIEVED A PARTIAL RESPONSE TO ADALIMUMAB AND WERE SUBSEQUENTLY SWITCHED TO SARILUMAB (2020) (0)
- Tackling oral health outcomes of osteoarthritis patients in austria: data from a multi-center osteoarthritis registry (2020) (0)
- RNASeq - 3D Organoids Reveal Cellular and Molecular Mechanisms of Synovial Tissue Formation 2/4 (2020) (0)
- FRI0664 DISEASE ACTIVITY IS THE MAJOR DISCRIMINATOR WHEN DEFINING REFRACTORY RHEUMATOID ARTHRITIS (2019) (0)
- FRI0144 Anemia Is A More Common Symptom in Late-Onset Ra Compared To Young-Onset RA and IS Stronger Related To Impaired Kidney Function (2016) (0)
- THU0245 Association of Autoantibodies with Disease Activity in Rheumatoid Arthritis (2014) (0)
- Reply to "Correspondence on "Re-examining remission definitions in RA: considering the DAS28, CRP level and patient global assessment" by Felson et al." (2021) (0)
- THU0070 Treat-to-target in ra: what level of treatment response is necessary by 3 months in order to achieve the treatment target by 6 months? results from a real life study (2017) (0)
- FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study (2017) (0)
- Web figure 2 (2013) (0)
- POS1079 CLINICAL CHARACTERIZATION OF PRODROMAL AND VERY EARLY PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW FOR THE DEFINITION OF CLINICAL AND IMAGING SUSPICIOUS FEATURES FOR PROGRESSION TO PSORIATIC ARTHRITIS (2022) (0)
- RNASeq - 3D Organoids Reveal Cellular and Molecular Mechanisms of Synovial Tissue Formation 4/4 (2020) (0)
- AB0466 Glucocorticoid Effect on Radiographic Progression in Rheumatoid Arthritis BIOLOGICS Trials (2014) (0)
- Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison (2023) (0)
- SAT0061 IMPORTANT ROLE OF CD11C+ CELLSIN INFLAMMATORY ARTHRITIS (2019) (0)
- THU0431 FREQUENCY OF TENDON INVOLVEMENT AND ITS EFFECT ON HAND FUNCTION IN HAND OSTEOARTHRITIS (2019) (0)
- Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study (2023) (0)
- THU0701 The effects of structural damage on functional disability in psoriatic arthritis (2017) (0)
- P281 52-Week efficacy and safety of ixekizumab in r-axSpA/AS patients naïve to biologic treatments or with prior inadequate response/intolerance to tumor necrosis factor inhibitors (2020) (0)
- FRI0665 THE ROLE OF CLINICAL JOINT INFLAMMATION AND ACUTE PHASE RESPONSE ON STRUCTURAL PROGRESSION OF PATIENTS WITH PSORIATIC ARTHRITIS (2019) (0)
- IL-6: To immunity and beyond (2018) (0)
- THU0110 The importance of sustained remission for longterm outcomes in patients with rheumatoid arthritis (2017) (0)
- SAT0194 Sirukumab integrated safety in rheumatoid arthritis patients: analysis of the sirround phase 3 data (2017) (0)
- Distinct galectin profile in inflammation-mediated cartilage damage (2020) (0)
- AB0277 EFFECT OF DISEASE DURATION AND OTHER PATIENT BASELINE CHARACTERISTICS ON OUTCOMES IN TOCILIZUMAB-TREATED RHEUMATOID ARTHRITIS PATIENTS: A POOLED ANALYSIS (2019) (0)
- AB1346 Rheumatoid factor (RF), not antibodies to citrullinated proteins (ACPA), may be associated with high disease activity (2013) (0)
- Malignant disease Rheumatic disease Natural course Treatment Treatment (2011) (0)
- AB0271 Changes of serological markers in early and established rheumatoid arthritis (RA) during the course of traditional and biological disease modifying therapy (2013) (0)
- FRI0631 Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction quality appraisal tool (2018) (0)
- POS1441 SYMPTOMS CHARACTERISTICS OF SEROPOSITIVE INDIVIDUALS AT-RISK FOR DEVELOPING RHEUMATOID ARTHRITIS ARE VERSATILE AND COMPARABLE TO THOSE IN PEOPLE WITH EARLY RHEUMATOID ARTHRITIS (2021) (0)
- Treating Rheumatic Diseases to Target: A Story of Success. (2019) (0)
- AB0718 Immune-apheresis in patients with inflammatory myopathies, a case series. (2022) (0)
- SAT0688 Progressive drift of patient populations in rheumatoid arthritisclinical trials over time (2018) (0)
- FRI0207 Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate, methotrexate alone or placebo: the dinora trial (2017) (0)
- What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis (2023) (0)
- AB1177 SEXUALITY, FAMILY PLANNING AND MENTAL HEALTH AMONG REPRODUCTIVE-AGE WOMEN WITH RHEUMATIC DISEASE DURING THE COVID-19 PANDEMIC (2022) (0)
- Reply: To PMID 23686535. (2014) (0)
- FRI0214 Long-term efficacy and safety of sirukumab in patients with active rheumatoid arthritis despite anti-tumor necrosis factor therapy: results of the randomized, phase 3 sirround-t study (2017) (0)
- The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination (2023) (0)
- SP0212 HIGHLIGHTS FROM THE SCIENTIFIC PROGRAMME (2019) (0)
- THU0188 EFFICACY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH POOR PROGNOSTIC FACTORS: POST HOC ANALYSIS OF FINCH 3 (2020) (0)
- Effective Treatment Strategies for Rheumatoid Arthritis (2013) (0)
- Response to: Correspondence on ‘Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment’ by Felson et al (2022) (0)
- Somatisation: a joint responsibility of doctor and patient (2006) (0)
- FRI0568 Disease Activity States of The Dapsa, A Psoriatic Arthritis Specific Instrument, Are Valid against The Constructs of Functional Status and Structural Progression (2016) (0)
- POS0563 INFLUENCE OF ACTIVE VERSUS PLACEBO CONTROL ON TREATMENT RESPONSES IN RANDOMIZED CONTROLLED TRIALS IN RHEUMATOID ARTHRITIS (2022) (0)
- POS0911 DIAGNOSTIC VALUE AND CLINICAL RELEVANCE OF MUSCLE BIOPSY IN PATIENTS WITH SUSPECTED MYOSITIS (2022) (0)
- The slippery road of adherence in chronically ill individuals. (2019) (0)
- Developing guidelines for ultrarare rheumatic disorders: a bumpy ride (2022) (0)
- Message from the new EULAR President and Steering Group (2021) (0)
- Is computer-assisted management necessary for patients with early rheumatoid arthritis? (2008) (0)
- POS0704 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE, WITH 4 OR <4 POOR PROGNOSTIC FACTORS: A POST HOC ANALYSIS OF THE FINCH 1 STUDY (2022) (0)
- Reply (2014) (0)
- Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials (2022) (0)
- Outcomes assessment in rheumatic disease (2007) (0)
- Preanalytical stability of SARS-CoV-2 anti-nucleocapsid antibodies (2022) (0)
- SAT0575 Disease Activity in Psoriatic Arthritis (PSA): Defining Remission and Treatment Success Using the Dapsa-Score (2015) (0)
- RNASeq - 3D Organoids Reveal Cellular and Molecular Mechanisms of Synovial Tissue Formation 1/4 (2020) (0)
- AB1084 Treatment Patterns and Retention in an Inception Cohort of 309 RA Patients (2014) (0)
- SAT0643-HPR Points To Consider for Health Professionals Undertaking Musculoskeletal Ultrasound for Rheumatic and Musculoskeletal Diseases: Progress of A Eular Task Force (2016) (0)
- Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE (2022) (0)
- FRI0125 Rheumatoid arthritis patients with anti-acetylated peptide antibodies starting their first tumor-necrose-factor-inhibitor treatment show greater response (2017) (0)
- POS1243 ACCELERATED WANING OF PROTECTIVE IMMUNITY AFTER SARS-CoV-2 mRNA VACCINATION IN PATIENTS TREATED WITH BIOLOGICAL AND TARGETED SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS (2022) (0)
- SAT0490 Ultrasound is a Valid Tool for Measuring Measurement Metacarpal Cartilage Thickness and Correlates with Joint Space Narrowing and Joint Space Width on X-Ray in Patients with Rheumatoid Arthritis (2013) (0)
- Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis? (2006) (0)
- AB0547 ASSOCIATION BETWEEN ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION WITH IMPROVEMENT IN QUALITY OF LIFE IN UPADACITINIB-TREATED PATIENTS IN THE PHASE 3 SELECT-PsA 1 AND 2 STUDIES (2021) (0)
- MULTI-PARAMETRIC PREDICTION MODELS FOR COVID-19 VACCINE SELECTION: RESULTS OF A COMPARATIVE POPULATION-BASED COHORT STUDY. (2022) (0)
- Rheumatoid Arthritis (2021) (0)
- AB0971 Change in Sonographic Cartilage Thickness Correlates with Change in Radiographic Joint Space Narrowing in The Metacarphalangeal Joints of Patients with Rheumatoid Arthritis (2016) (0)
- Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology (2020) (0)
- The undifferentiated arthritis dilemma: the story continues (2022) (0)
- The prozone effect in serum assays for IgG 4 : (0)
- SAT0091 Physical function continues to improve in sustained clinical remission of rheumatoid arthritis (RA) (2013) (0)
- THU0519 Chronicity of Rheumatoid Arthritis Affects the Responsiveness of Physical Function, but not of Disease Activity Measures in Rheumatoid Arthritis Clinical Trials (2013) (0)
- Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity Running head: Specificity of automated Anti-SARS-CoV-2 assays (2020) (0)
- Can imaging help unravel pain in psoriatic arthritis? (2021) (0)
- Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight-Joint Disease Activity Score, C-Reactive Protein Level, and Patient Global Assessment. (2021) (0)
- EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future (2021) (0)
- Diagnosis (2020) (0)
- THU0135 The Impact of Early Treatment with Adalimumab on Rheumatoid Factor and Anti-Citrullinated Peptide Antibody Levels in Patients with Rheumatoid Arthritis in The Optima Trial (2016) (0)
- Relation Between Disease Activity Indices and Their Individual Components and Radiographic Progression in Rheumatoid Arthritis : A Systematic Literature Review (2014) (0)
- Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination Stratagy (2023) (0)
- Response to: ‘Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis’ by Bugatti et al (2020) (0)
- The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care (2003) (0)
- The sensitivity improved two-test algorithm “SIT2”: a universal optimization strategy for SARS-CoV-2 serology (2020) (0)
- FRI0162 BASELINE CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH ANAEMIA IN CLINICAL STUDIES OF TOFACITINIB IN RHEUMATOID ARTHRITIS (2019) (0)
- POS0547 METEOROLOGICAL VARIABLES HAVE DIFFERENT INFLUENCE ON CORE MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS (2021) (0)
- Rheumatoid arthritis—diagnosis (2013) (0)
- RNASeq - 3D Organoids Reveal Cellular and Molecular Mechanisms of Synovial Tissue Formation 3/4 (2020) (0)
- AB0180 CLINICAL AND ULTRASOUND-BASED COMPOSITE DISEASE ACTIVITY INDICES AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS (2022) (0)
- POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES (2021) (0)
- Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss (2022) (0)
- FRI0108 Time to first treatment is associated with a refractory course of rheumatoid arthritis (2017) (0)
- AB1135 RESPONSE TO SARS-COV-2 VACCINATION IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE DEPENDS ON IMMUNOSUPPRESSIVE REGIMEN: A MATCHED, PROSPECTIVE COHORT STUDY (2022) (0)
- SAT0670 REDUCING THE IMPACT OF THE PATIENT GLOBAL ON BOOLEAN REMISSION CRITERIA FOR RHEUMATOID ARTHRITIS (2019) (0)
- P178 The impact of peripheral articular manifestations on the efficacy of ixekizumab in patients with radiographic axial spondyloarthritis (2021) (0)
- THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS (2020) (0)
- Standardisation of ACPA tests: evaluation of a new candidate reference preparation (2022) (0)
- POS1372 THE 2021 EULAR AND ACR POINTS TO CONSIDER FOR DIAGNOSIS, MANAGEMENT AND MONITORING OF THE IL 1 MEDIATED AUTOINFLAMMATORY DISEASES: CAPS, TRAPS, MKD, AND DIRA (2022) (0)
- Helliwell and Coates byusing the DAPSA score : response to letter Defining remission and treatment success (2015) (0)
- Treat to Target in Rheumatic Diseases: Rationale and Results (2019) (0)
- POS1390 ULTRASOUND BASED WITHDRAWAL OF BIOLOGICS IN RHEUMATOID ARTHRITIS (RA-BioStop) (2022) (0)
- FRI0024 Effectiveness and toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis (2001) (0)
- FRI0524 Reliability and smallest detectable difference of the patient global assessment in rheumatoid arthritis patients (2013) (0)
- SP0162 REMISSION IN RA: DOES THE DEFINITION MATTER? (2019) (0)
- Reply: To PMID 24757132. (2014) (0)
- THU0103 ANTI-RA33 autoantibodies are associated with therapeutic responses to methotrexate and ANTI-TNF treatment in patients with rheumatoid arthritis (2017) (0)
- How FABulous is PEGgy? Certoliziumab Pegol from the Bench to the Patients (2014) (0)
- Reply (2022) (0)
- Targeting p19 in psoriatic arthritis: more than just another therapeutic approach? (2020) (0)
- SAT0053 Persistence of Subclinical Joint Activity in Rheumatoid Arthritis Joints (2014) (0)
- Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature (2022) (0)
- POS0678 CLINICAL OUTCOMES OF METHOTREXATE (MTX)-NAIVE RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) ON FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL INITIALLY ON FIL OR MTX DURING THE PHASE 3 PARENT STUDY (PS) (2022) (0)
- FRI0082 Radiographic progression in rheumatoid arthritis in the 21st century (2013) (0)
- POS1026 PREDICTORS FOR ACHIEVEMENT OF LOW DISEASE ACTIVITY AT WEEK 56 IN PATIENTS WITH PSORIATIC ARTHRITIS WHO RECEIVED UPADACITINIB 15 MG ONCE DAILY: POOLED ANALYSIS OF TWO PHASE 3 STUDIES (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Daniel Aletaha?
Daniel Aletaha is affiliated with the following schools:
